Therapeutic aspects of melatonin applications
https://doi.org/10.21518/2079-701X-2021-10-80-84
Abstract
The results of multicenter clinical trials show the broad potential of melatonin since discovery of this adaptogen to the present day. Melatonin is a neuropeptide that is synthesized mainly in the small brain gland, the pineal gland, and has a unique effect in humans and animals. Using melatonin, the pineal gland participates in the organization of circadian periodism and regulation of cyclic processes, acting as an intermediary between the pacemaker mechanism of the suprachiasmatic nuclei (SCN) and peripheral organs. The pineal gland and the SCN of the hypothalamus form part of the system of the so-called biological clock of the body, which plays a key role in the mechanisms of regulation of the biological clock via circadian rhythms and ageing. Initially, melatonin was only considered a hormone involved in the synchronization of the mechanisms of the circadian rhythm, but later it was found that, in addition to this hormonal function, it takes part in the regulation of the seasonal cycle in animals and humans.
At present, melatonin drugs have shown high efficacy and safety in various sleep-wake disorders regardless of their genesis, disorganization of circadian rhythms, stress adjustment disorders, rapid change of time zones, shift work and in complex therapy of patients with cerebrovascular diseases.
The article considers the multimodal capabilities of melatonin, including adaptogenic, biorhythmogenic, hypnotic, immunostimu-lating, antioxidant effects. The role of melatonin in the treatment of various central nervous system disorders, including neurodegenerative diseases, has been determined.
The review emphasizes the wide-ranging effects of melatonin and offers great opportunities for measuring melatonin as a biomarker for early detection and follow-up of various diseases.
About the Authors
S. L. Tsenteradze
University Clinical Hospital No. 3, Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Sergo L. Tsenteradze, Somnologist, Neurologist of the Department of Sleep Medicine, General Hospital Staff, University Clinical Hospital No. 3.
11, Bldg. 1, Rossolimo St., Moscow, 119435
M. G. Poluektov
University Clinical Hospital No. 3, Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Mikhail G. Poluektov, Cand. Sci. (Med.), Associate Professor, Head of the Department of Sleep Medicine.
11, Bldg. 1, Rossolimo St., Moscow, 119435
References
1. Lerner A.B., Case J.D., Takahashi Y., Lee T.H., Mori W. Isolation of Melatonin, the Pineal Gland Factor that Lightens Melanocytes. JAm Chem Soc. 1958;80(10):2587. https://doi.org/10.1021/ja01543a060.
2. Axelrod J, Weissbach H. Enzymatic O-Methylation of N-Acetylserotonin to Melatonin. Science. 1960;131(3409):1312. https://doi.org/10.1126/sci-ence.131.3409.1312.
3. Karasek K., Winczyk K. Melatonin in Humans. J Physiol Pharmacol. 2006;57(5): 19-39. Available at: https://pubmed.ncbi.nlm.nih.gov/17218758/.
4. Bubenik G.A. Gastrointestinal Melatonin: Localization, Function, and Clinical Relevance. Dig Dis Sci. 2002;47(10):2336-2348. https://doi.org/10.1023/a:1020107915919.
5. Slominski A., Wortsman J., Tobin DJ. The Cutaneous Serotoninergic/ Melatoninergic System: Securing a Place under the Sun. FASEB J. 2005;19(2):176-194. https://doi.org/10.1096/fj.04-2079rev.
6. Adan A., Archer S.N., Hidalgo M.P., Di Milia L., Natale V., Randler C. Circadian Typology: A Comprehensive Review. Chronobiol Int. 2012;29(9):1153-1175. https://doi.org/10.3109/07420528.2012.719971.
7. Waldhauser F., Weiszenbacher G., Frisch H., Zeitlhuber U., Waldhauser M., Wurtman RJ. Fall in Nocturnal Serum Melatonin during Prepuberty and Pubescence. Lancet. 1984;1(8373):362-365. https://doi.org/10.1016/s0140-6736(84)90412-4.
8. Waldhauser F., Saletu B., Trinchard-Lugan I. Sleep Laboratory Investigations on Hypnotic Properties of Melatonin. Psychopharmacology (Berl). 1990;100(2): 222-226. https://doi.org/10.1007/BF02244410.
9. Lynch HJ.,Wurtman RJ., Moskowitz M.A., Archer M.C., Ho M.H. Daily Rhythm in Human Urinary Melatonin. Science. 1975;187(4172):169-171. https://doi.org/10.1126/science.1167425.
10. Zawilska J.B., Skene DJ., Arendt J. Physiology and Pharmacology of Melatonin in Relation to Biological Rhythms. Pharmacol Rep. 2009;61(3):383-410. https://doi.org/10.1016/s1734-1140(09)70081-7.
11. Becker-Andre M., Wiesenberg I., Schaeren-Wiemers N., Andre E., Missbach M., Saurat J.H., Carlberg C. Pineal Gland Hormone Melatonin Binds and Activates an Orphan of the Nuclear Receptor Superfamily. J Biol Chem. 1994;269(46):28531-28534. Available at: https://www.jbc.org/article/S0021-9258(19)61934-4/pdf.
12. Bubenik G.A., Konturek SJ. Melatonin and Aging: Prospects for Human Treatment. J Physiol Pharmacol. 2011;62(1):13-19. Available at: http://www.jpp.krakow.pl/journal/archive/02_11/pdf/13_02_11_article.pdf.
13. Poeggeler B. Melatonin, Aging, and Age-Related Diseases: Perspectives for Prevention, Intervention, and Therapy. Endocrine. 2005;27(2):201-212. https://doi.org/10.1385/ENDO:27:2:201.
14. Oaknin-Bendahan S., Anis Y., Nir I., Zisapel N. Effects of Long-Term Administration of Melatonin and a Putative Antagonist on the Ageing Rat. Neuroreport. 1995;6(5):785-788. https://doi.org/10.1097/00001756-199503270-00020.
15. Reiter RJ., Rosales-Corral S.A., Tan D.X., Acuna-Castroviejo D., Oin L., Yang S.F., Xu K. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci. 2017;18(4):843. https://doi.org/10.3390/ijms18040843.
16. Fahn S., Cohen G. The Oxidant Stress Hypothesis in Parkinson's Disease: Evidence Supporting It. Ann Neurol. 1992;32(6):804-812. https://doi.org/10.1002/ana.410320616.
17. Carrillo-Vico A., Reiter RJ., Lardone PJ., Herrera J.L., Fernandez-Montesinos R., Guerrero J.M., Pozo D. The Modulatory Role of Melatonin on Immune Responsiveness. Curr Opin Investig Drugs. 2006;7(5):423-431. Available at: https://europepmc.org/article/med/16729718.
18. Hriscu M.L. Modulatory Factors of Circadian Phagocytic Activity. Ann N Y Acad Sci. 2005;1057:403-430. https://doi.org/10.1196/annals.1356.032.
19. Rasmussen D.D., Boldt B.M., Wilkinson C.W., Yellon S.M., Matsumoto A.M. Daily Melatonin Administration at Middle Age Suppresses Male Rat Visceral Fat, Plasma Leptin, and Plasma Insulin to Youthful Levels. Endocrinology. 1999;140(2):1009-1012. https://doi.org/10.1210/endo.140.2.6674.
20. Koyama H., Nakade O., Takada Y., Kaku T., Lau K.H. Melatonin at Pharmacologic Doses Increases Bone Mass by Suppressing Resorption through Down-Regulation of the RANKL-Mediated Osteoclast Formation and Activation. J Bone Miner Res. 2002;17(7):1219-1229. https://doi.org/10.1359/jbmr.2002.17.7.1219.
21. Silman R. Melatonin and the Human Gonadotrophin-Releasing Hormone Pulse Generator. J Endocrinol. 1991;128(1):7-11. https://doi.org/10.1677/joe.0.1280007.
22. Brzezinski A., Vangel M.G., Wurtman RJ., Norrie G., Zhdanova I., Ben-Shushan A., Ford I. Effects of Exogenous Melatonin on Sleep: A MetaAnalysis. Sleep Med Rev. 2005;9(1):41-50. https://doi.org/10.1016/j.smrv.2004.06.004.
23. Attenburrow M.E., Dowling B.A., Sharpley A.L., Cowen PJ. Case-Control Study of Evening Melatonin Concentration in Primary Insomnia. BMJ. 1996;312(7041):1263-1264. https://doi.org/10.1136/bmj.312.7041.1263.
24. Jonas M., Garfinkel D., Zisapel N., Laudon M., Grossman E. Impaired Nocturnal Melatonin Secretion in Non-Dipper Hypertensive Patients. Blood Press. 2003;12(1):19-24. Available at: https://pubmed.ncbi.nlm.nih.gov/12699131/.
25. Miller S.C., Pandi-Perumal S.R., Esquifino A.I., Cardinali D.P., Maestroni GJ. The Role of Melatonin in Immuno-Enhancement: Potential Application in Cancer. Int J Exp Pathol. 2006;87(2):81-87. https://doi.org/10.1111/j.0959-9673.2006.00474.x.
26. Carman J.S., Post R.M., Buswell R., Goodwin F.K. Negative Effects of Melatonin on Depression. Am J Psychiatry. 1976;133(10):1181-1186. https://doi.org/10.1176/ajp.133.10.1181.
27. Jagota A., Mattam U. Daily Chronomics of Proteomic Profile in Aging and Rotenone-Induced Parkinson's Disease Model in Male Wistar Rat and Its Modulation by Melatonin. Biogerontology. 2017;18(4):615-630. https://doi.org/10.1007/s10522-017-9711-y.
28. Pei Z., Pang S.F., Cheung R.T. Administration of Melatonin after Onset of Ischemia Reduces the Volume of Cerebral Infarction in a Rat Middle Cerebral Artery Occlusion Stroke Model. Stroke. 2003;34(3):770-775. https://doi.org/10.1161/01.STR.0000057460.14810.3E.
29. Han F., Chen Y.X., Lu Y.M., Huang J.Y., Zhang G.S., Tao R.R. et al. Regulation of the Ischemia-Induced Autophagy-Lysosome Processes by Nitrosative Stress in Endothelial Cells. J Pineal Res. 2011;51(1):124-135. https://doi. org/10.1111/j.1600-079X.2011.00869.x.
30. Paul M.A., Gray G., Kenny G., Pigeau R.A. Impact of Melatonin, Zaleplon, Zopiclone, and Temazepam on Psychomotor Performance. Aviat Space Environ Med. 2003;74(12):1263-1270. Available at: https://www.research-gate.net/publication/8945690_Impact_of_Melatonin_Zaleplon_Zopiclone_and_Temazepam_on_Psychomotor_Performance.
31. Barchas J., DaCosta F., Spector S. Acute Pharmacology of Melatonin. Nature. 1967;214(5091):919-920. https://doi.org/10.1038/214919a0.
32. Andersen L.P., Werner M.U., Rosenkilde M.M., Fenger A.O., Petersen M.C., Rosenberg J., Gogenur I. Pharmacokinetics of High-Dose Intravenous Melatonin in Humans. J Clin Pharmacol. 2016;56(3):324-329. https://doi.org/10.1002/jcph.592.
Review
For citations:
Tsenteradze SL, Poluektov MG. Therapeutic aspects of melatonin applications. Meditsinskiy sovet = Medical Council. 2021;(10):80-84. (In Russ.) https://doi.org/10.21518/2079-701X-2021-10-80-84
Views:
809
Email this article 